Figure 2. Risk of vertebral fracture relative to placebo for subjects at high risk for fracture, by agent*.

Figure 2. Risk of vertebral fracture relative to placebo for subjects at high risk for fracture, by agent*

* High-risk: 1) transplant population, or 2) study entry criteria require T score ≤-2.5, or 3) study entry criteria require≥1 fracture, or 4) ≥ 50% population has 1 or more fractures at baseline or 5) Significant neuromuscular impairment. Intermediate-risk: 1) study entry criteria require T score ≤1.5, or 2) 10–50% of population has one or more fracture at baseline, or 3) study population has chronic disease that is commonly treated with glucocorticoids or 4) in the absence of data on BMD or fractures, mean age of population > 62 years.
† Pooled risk estimate from cited meta-analys(is)(es) or systematic review(s).
‡ Pooled risk estimate calculated by authors; restricted to studies with > 12 months of follow-up.
§ Risk estimate calculated from cited individual study.
** Insufficient data to calculate risk.

From: 3, Results

Cover of Comparative Effectiveness of Treatments To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis
Comparative Effectiveness of Treatments To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis [Internet].
Comparative Effectiveness Reviews, No. 12.
MacLean C, Alexander A, Carter J, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.